Category: 23828-92-4

In 2019,International Research Journal of Pharmacy included an article by Wadher, Sailesh J.; Supekar, Bhagwan B.; Shivpuje, Shivraj S.. Synthetic Route of C13H19Br2ClN2O. The article was titled 《Development and validation of new FT-IR spectrophotometric method for simultaneous estimation of ambroxol hydrochloride and cetirizine hydrochloride in combined pharmaceutical solid tablet dosage form》. The information in the text is summarized as follows:

IR spectroscopy is also known as vibrational spectroscopy. FTIR is a non-destructive, highly sensitive, highly specific and robust anal. technique by which almost any solid, liquid or gas samples can be analyzed. The given research work is related with successful development and validation of newer, accurate, precise and sensitive FT-IR anal. method for estimation of cetirizine hydrochloride and ambroxol hydrochloride in their combined tablet dosage form. Literature survey reveals that, there is no FT-IR spectrophotometric method was developed and validated until now for this combination. KBr (Ar) grade was used as diluent. The functional groups were selected as AR-NH (1631 cm-1) for ambroxol HCl and C=O (1741 cm-1) for cetirizine HCl. The method was validated as per ICH guidelines. The linearity was developed at 6.0-36.0% weight/weight for AMB HCl and 0.5-3.0% weight/weight for CET HCl resp. The correlation coefficients were found to be 0.9993 and 0.9995 resp. The precision was found to be within acceptable limit. The developed method was found to be accurate and repeatable the % RSD was found to be within 2%. The results came from multiple reactions, including the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Synthetic Route of C13H19Br2ClN2O)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a medication indicated to alleviate chest congestion associated with conditions that include bronchitis, pneumonia, bronchospasm asthma, cough, and allergy.Synthetic Route of C13H19Br2ClN2O Preclinically, ambroxol, the active ingredient of Mucosolvan, has been shown to increase respiratory tract secretion.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《A study on drug prescribing pattern, drug interaction and evaluation of medication adherence among smoking and non-smoking chronic obstructive pulmonary disease patients in tertiary care teaching hospital》 was published in Indo American Journal of Pharmaceutical Research in 2022. These research results belong to Jose, Anupriya; Sojan, Sonu Maria; Ritesh, Sinha; Kumar, T. Chaithanya. SDS of cas: 23828-92-4 The article mentions the following:

The aim of the study is to assess the Drug Prescribing Pattern, Drug Interaction and Evaluation of Medication Adherence among Smoking and Non-smoking Chronic Obstructive Pulmonary Disease Patients in Tertiary Care Teaching Hospital. The primary objectives of the study is to access the drug prescribing pattern, and to determine various etiologies in non-smoker COPD patients. This study identifies drug interactions based on their severity and medication adherence in smoker and non-smoker patients. A Prospective, Observational and Hospital based study was conducted on patients admitted in a tertiary care teaching hospital for a period of 6 mo. Data regarding patient′s demog. details, the prescription of the patient who are treated during the course of the study are audited prospectively using a specifically predesigned proforma. The study reveals that males (51.33%) were more likely to have COPD in which majority of patients were nonsmoker (68%) above 60 years of age. Among all medications the major class of drugs prescribed were Antibiotics, Bronchodilator, Corticosteroids and least were Antitussives. The present study concluded that proportion of nonsmoker COPD patients are higher than smokers due to multiple risk factor in which outdoor air pollution was the most leading factor. Most of the patients have low motivation and low knowledge. The major reasons for medication non-compliance were felt better and stopped, forget to take and refill. The study also reveals improving medication adherence among individuals with COPD is critical to optimizing patient outcomes. By providing effective counselling, medication adherence to the treatment can be achieved. In the experiment, the researchers used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4SDS of cas: 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.SDS of cas: 23828-92-4 It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Simultaneous estimation of salbutamol sulphate and ambroxol HCl from their combined dosage form by UV-VIS spectroscopy using simultaneous equation method》 were Panchale, Wrushali A.; Gulhane, Chaitanya A.; Manwar, Jagdish V.; Bakal, R. L.. And the article was published in GSC Biological and Pharmaceutical Sciences in 2020. SDS of cas: 23828-92-4 The author mentioned the following in the article:

A simple UV-Vis Spectrophometric method was developed for the simultaneous determination of salbutamol sulfate and ambroxol HCl (AMB) from their combined dosage form. The method employs formation and solving of simultaneous equation using 242 nm and 272 nm as two anal. wavelengths (λMax of the drugs) of detection. Both the drugs obeyed Beer-Lambert’s law over the concentration range 1-50μg/mL for salbutamol sulfate and 10-50μg/mL for ambroxol HCl, resp. The developed method was validated for Accuracy, Precision, Limit of Detection and Limit of Quantification as per ICH guidelines and results of anal. were validated statistically. In the experiment, the researchers used many compounds, for example, trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4SDS of cas: 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.SDS of cas: 23828-92-4 It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《First-order derivative spectrophotometric estimation of gemifloxacin mesylate and ambroxol HCl in tablet dosage form》 were Panchale, Wrushali A.; Bakal, Ravindra L.. And the article was published in GSC Biological and Pharmaceutical Sciences in 2021. Related Products of 23828-92-4 The author mentioned the following in the article:

Aim of present work was to develop and validate a simple, precise and accurate uv-vis spectrophotometric method for the simultaneous estimation of gemifloxacin mesylate (GEMI) and ambroxol HCl (AMB) in their combined tablet dosage form. The method is based on first-order derivative spectroscopy. For determination of sampling wavelengths, each of GEMI and AMB were scanned in the wavelength range of 200-400 nm in the spectrum mode and sampling wavelengths were selected at 360 nm (zero crossing of GEMI) where AMB showed considerable absorbance and at 221.6 nm (zero crossing of AMB) where GEMI showed considerable absorbance. The linearity was obtained in the concentration range of 32-192μg/mL for GEMI and 7.5-45μg/mL for AMB. The correlation coefficients were found to be 0.9987 and 0.9992 for GEMI and AMB, resp. The method was validated as per ICH guidelines. Mean recoveries were found satisfactory. All the data of validation study was found to be satisfactorily. The proposed method can be applied for simultaneous estimation of both the drugs. In the experiment, the researchers used many compounds, for example, trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Related Products of 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Related Products of 23828-92-4 It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Concurrent analysis of ambroxol HCl and salbutamol sulphate from tablet formulation by RP-HPLC》 were Panchale, Wrushali A.; Badukle, Neha A.; Sabhadinde, Amar F.; Bakal, Ravindra L.; Manwar, Jagdish V.. And the article was published in GSC Biological and Pharmaceutical Sciences in 2020. Formula: C13H19Br2ClN2O The author mentioned the following in the article:

RP-HPLC method was developed for concurrent anal. of ambroxol HCl and salbutamol sulfate from tablet formulation. Analytes were separated with mobile phase consisting of mixture of methanol and water (0.1% triethylamine) in the ratio 50: 50 at a flow rate of 0.7 mL/min with Nucleosil (4.6 mm I.D x 250 mm) C18 column. The retention time of ambroxol HCl and salbutamol sulfate was found to be 3.61 and 6.20 min, resp. The detection was carried out at 224 nm. The dynamic range for ambroxol HCl and salbutamol sulfate observed was 15-75μg/mL and 1-5μg/mL, resp. The percent recovery obtained for ambroxol HCl and salbutamol sulfate were close to 100%. Obtained statistical data of results was found to satisfactorily.trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Formula: C13H19Br2ClN2O) was used in this study.

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Formula: C13H19Br2ClN2O It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Application of two advanced derivative spectrophotometric methods for simultaneous estimation of salbutamol sulphate, ambroxol hydrochloride and theophylline in pure and commercial formulations》 was written by Dave, H. N.; Mashru, R. C.. Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride And the article was included in International Journal of Current Pharmaceutical Research in 2022. The article conveys some information:

Two advanced spectrophotometric methods have been proposed for the simultaneous determination of Salbutamol sulfate, Ambroxol hydrochloride and Theophylline in pure and pharmaceutical formulations. The proposed methods exclude the hectic steps of time-consuming sample preparations or purification or separation steps. There is no any spectrophotometric method has been avail for simultaneous estimation of the ternary mixture containing Salbutamol sulfate, Ambroxol hydrochloride and Theophylline. The methods are derivative ratio spectra zero-crossing method and double divisor ratio spectra derivative method resp. Both the methods are found to be rapid, accurate, precise, reliable and economical as well. The developed methods show best results in terms of linearity, accuracy, precision, limit of detection and limit of quantification for standard laboratory mixtures of pure drugs and marketed formulations. The range for Salbutamol sulfate, Ambroxol hydrochloride and Theophyllineare found to be 1-35μg ml-1, 5-35μg ml-1 and 6-60μg ml-1 resp. For the derivative ratio spectra zero-crossing method, the values of the limit of detection are found to be 0.3161μg ml-1, 0.2212μg ml-1 and 0.2910μg ml-1 and the values limit of quantification are found to be 0.9571μg ml-1, 0.7412μg ml-1 and 0.9671μg ml-1 for Salbutamol sulfate, Ambroxol hydrochloride and Theophylline resp. For double divisor ratio spectra derivative method, limit of detection values is found to be 0.3251μg ml-1, 0.2591μg ml-1 and 0.2640μg ml-1 and the limit of quantification values are found to be 0.9870μg ml-1, 0.8650μg ml-1 and 0.8812μg ml-1 for Salbutamol sulfate, Ambroxol hydrochloride and Theophylline resp. The common excipients and additives did not interfere in the determinations of any of the drugs while being analyzed for com. formulations. These two spectrophotometric methods, which determine SS, AH, and THE simultaneously, are simple, specific, accurate, precise, rapidly, and economically, indicating that they can be used routinely in pharmaceutical anal. As a result, derivative spectrophotometry may be used effectively for the simultaneous determination of SS, AH and THE in the combined dosage forms without any prior separation of individual drugs. The experimental process involved the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Reference of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Yu, Li; Bhattacharya, Dhruva; Wang, Zhenhan; Wang, Mingwu published an article in Graefe’s Archive for Clinical and Experimental Ophthalmology. The title of the article was 《Topical administration of ambroxol eye drops augments tear secretion in rabbits》.Synthetic Route of C13H19Br2ClN2O The author mentioned the following in the article:

To investigate if topical administration of ambroxol promotes tear secretion and to compare with Diquas ophthalmic eye drop. Two consecutive studies were conducted using sixteen (32 eyes) New Zealand White rabbits. The first study compared the efficacy of ambroxol hydrochloride (0.05%, 0.2%, and 1.0%) on tear and mucin secretion when administered twice daily. Tear secretion was assessed by Schirmer test I and mucin production by conjunctival impression cytol. and PAS stain. The second study compared 0.2% ambroxol hydrochloride with Diquas. A human goblet cell line and human conjunctival tissue were used to test the effect of ambroxol hydrochloride on the expression of aquaporin 5 (AQP5) and MUC5AC, using reverse transcriptase-quant. polymerase chain reaction and immunoblotting. All three concentrations of ambroxol hydrochloride demonstrated significant efficacy on tear stimulation within 2 wk of treatment and total mucin component appeared increased. When administered topically twice daily, 0.2% ambroxol hydrochloride was more effective in augmenting tear secretion than Diquas. With 24 h of treatment, 5μM of ambroxol hydrochloride upregulated AQP5 and MU5AC mRNA and MUC5AC protein in a goblet cell line. When tested on preserved human conjunctiva tissue, a trend of increased production of MUC5AC protein was seen (P = 0.26). Ambroxol is effective in augmenting tear secretion at the ocular surface in rabbits. With actions desirable of a candidate dry eye drug, further investigation of ambroxol and related compounds is warranted to explore their value toward clin. application. The experimental part of the paper was very detailed, including the reaction process of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Synthetic Route of C13H19Br2ClN2O)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Synthetic Route of C13H19Br2ClN2O It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Analysis of Using the Total White Blood Cell Count to Define Severe New-onset Ulcerative Colitis in Children》 were Mack, David R.; Saul, Bradley; Boyle, Brendan; Griffiths, Anne; Sauer, Cary; Markowitz, James; LeLeiko, Neal; Keljo, David; Rosh, Joel R.; Baker, Susan S.; Steiner, Steve; Heyman, Melvin B.; Patel, Ashish S.; Baldassano, Robert; Noe, Joshua; Rufo, Paul; Kugathasan, Subra; Walters, Thomas; Marquis, Alison; Thomas, Sonia M.; Denson, Lee; Hyams, Jeffrey. And the article was published in Journal of Pediatric Gastroenterology and Nutrition in 2020. Related Products of 23828-92-4 The author mentioned the following in the article:

The aim of this study was to assess common laboratory tests in identifying severe ulcerative colitis in children at diagnosis. A cohort of 427 children 4 to 17 years of age newly diagnosed with ulcerative colitis (UC) was prospectively enrolled. Boosted classification trees were used to characterize predictive ability of disease attributes based on clin. disease severity using Pediatric Ulcerative Colitis Activity Index (PUCAI), severe (65+) vs. not severe (<65) and total Mayo score, severe (10-12) vs. not severe (<10); mucosal disease by Mayo endoscopic subscore, severe (3) vs. not severe (<3); and extensive disease vs. not extensive (left-sided and proctosigmoiditis). Mean age was 12.7 years; 49.6% (n = 212) were girls, and 83% (n = 351) were Caucasian. Severe total Mayo score was present in 28% (n = 120), mean PUCAI score was 49.820.1, and 33% (n = 142) had severe mucosal disease with extensive involvement in 82% (n = 353). Classification and regression trees identified white blood cell count, erythrocyte sedimentation rate, and platelet count (PLT) as the set of 3 best blood laboratory tests to predict disease extent and severity. For mucosal severity, albumin (Alb) replaced PLT. Classification models for PUCAI and total Mayo provided sensitivity of at least 0.65 using standard clin. cut-points with misclassification rates of approx. 30%. A combination of the white blood cell count, erythrocyte sedimentation rate, and either PLT or albumin is the best predictive subset of standard laboratory tests to identify severe from nonsevere clin. or mucosal disease at diagnosis in relation to objective clin. scores. After reading the article, we found that the author used trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Related Products of 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Related Products of 23828-92-4 It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The author of 《Formulation and in-vitro characterization of ambroxol hydrochloride sustained-release matrix tablets》 were Jaya, S.; Srilaxmi, G.. And the article was published in International Journal of Pharmaceutical Sciences and Research in 2019. Computed Properties of C13H19Br2ClN2O The author mentioned the following in the article:

The present study involves the formulation and in-vitro characterization of sustained release matrix tablets of Ambroxol hydrochloride, a potent mucolytic agent used in the treatment of respiratory disorders. FTIR anal. confirmed the absence of drug-polymer interactions. Sustained release matrix tablets containing 75 mg were formulated employing HPMCK15 and xanthan gum as release retarding polymer and dicalcium phosphate and microcrystalline cellulose as diluents. The powder blend was evaluated for micromeritic properties. The matrix tablets were prepared by direct compression technique. The prepared tablets were evaluated for uniformity of weight, hardness, friability, and uniformity of content. All the formulations showed compliance with pharmacopoeial standards The in-vitro drug release studies were carried out for a period of 12 h using USP type II dissolution apparatus at 50 rpm by taking 900 mL of 0.1 N HCl (pH 1.2) as dissolution medium for first 2 h and later replacing it with 900 mL pH 6.8 phosphate buffer solution for a period of 10 h at 37 ± 0.5°C. Among the different combinations of polymers in different ratios studied, the desired in-vitro drug release (97.65% for 12 h) was found with the combination of HPMC K15M and xanthan gum with the drug in the ratio of 1: 0.75 (F7). The drug release from the F7 formulation followed zero order kinetics and mechanism was found to be erosion. In the experimental materials used by the author, we found trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Computed Properties of C13H19Br2ClN2O)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) is a mucolytic expectorant and a metabolite of bromhexine.Computed Properties of C13H19Br2ClN2O It is used in the treatment of respiratory disorders characterized by viscous or excessive mucus.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

《Development and validation of RP-HPLC method for the simultaneous estimation of salbutamol sulphate and ambroxol hydrochloride in oral liquid dosage form》 was published in Asian Journal of Pharmaceutical Research and Development in 2021. These research results belong to Kumar, Rakesh; Bansal, Mukesh; Agarwal, Dilip. Related Products of 23828-92-4 The article mentions the following:

Pharmaceutical anal. is imported branch of science deals with to check the identity, strength, quality and purity of chem. and herbal compounds Qual. anal. of drugs and pharmaceutical compounds Quant. anal. is of much importance and done by various methods. One of the most accurate and precise methods is spectrophotometry which comprises the measurement of intensity of electromagnetic radiation emitted or absorbed by the compound Another most popular method of for quant. anal. is high performance liquid chromatog. (HPLC). In the present article a RP-HPLC method was developed for the simultaneous determination of salbutamol sulfate and ambroxol hydrochloride in oral liquid doses form and validation of the developed method. Developed methods include selection of mobile phase, chromatog. method, and wavelength whereas validation involves the system suitability, accuracy, precision, linearity, reproducibility, robustness, specificity and solution stability of the developed method. The result showed that the developed method is the best suited to the simultaneous determination of salbutamol sulfate and ambroxol hydrochloride and validated as per the standards The results came from multiple reactions, including the reaction of trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4Related Products of 23828-92-4)

trans-4-((2-Amino-3,5-dibromobenzyl)amino)cyclohexanol hydrochloride(cas: 23828-92-4) enhances pulmonary surfactant production and stimulates ciliary activity.Related Products of 23828-92-4 It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts